Apr 21 2015
CorTechs Labs, the leading medical software innovator providing solutions for quantitative brain volume analysis is pleased to announce a partnership agreement with Novartis Pharma AG, a global pharmaceutical company. The companies will collaborate to develop NeuroQuant's powerful brain volume quantification report targeting the identification, measurement and tracking of brain volume loss in multiple sclerosis patients.
The resulting report enables clinicians to automatically conduct accurate and consistent measurements of the whole brain, left and right thalami and the lateral ventricles out of 3D T1 MRI images. The report is targeting the identification and tracking of neurodegeneration in these sub-cortical structures. This breakthrough solution, which is available both online and as an installed software solution, provides neurologists and radiologists with objective support of brain volume loss and its changes over time and as compared to normative values.
"We're pleased to partner with Novartis to advance the clinical care and assessment of multiple sclerosis worldwide," said Guri Stark, CorTechs Labs' CEO. "We believe this partnership will empower clinicians with objective quantitative data, while continuing NeuroQuant's growth momentum. This, in-turn furthers our vision to establish NeuroQuant as the standard measurement solution for all brain disorders, including Alzheimer's disease, epilepsy, multiple sclerosis and traumatic brain injury."
Anxiety and negative emotions reduced by brain circuit that consciously slows breathing